COVID-19 Booster Dose Vaccination Coverage and Factors Associated with Booster Vaccination among Adults, United States, March 2022.
COVID-19
National Immunization Survey-Adult COVID Module
United States
adults
booster vaccination
coronavirus disease
coverage
dose
factors
provider recommendation
respiratory infections
vaccination coverage
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pubmed:
9
12
2022
medline:
27
12
2022
entrez:
8
12
2022
Statut:
ppublish
Résumé
The Centers for Disease Control and Prevention recommends a COVID-19 vaccine booster dose for all persons >18 years of age. We analyzed data from the National Immunization Survey-Adult COVID Module collected during February 27-March 26, 2022 to assess COVID-19 booster dose vaccination coverage among adults. We used multivariable logistic regression analysis to assess factors associated with vaccination. COVID-19 booster dose coverage among fully vaccinated adults increased from 25.7% in November 2021 to 63.4% in March 2022. Coverage was lower among non-Hispanic Black (52.7%), and Hispanic (55.5%) than non-Hispanic White adults (67.7%). Coverage was 67.4% among essential healthcare personnel, 62.2% among adults who had a disability, and 69.9% among adults who had medical conditions. Booster dose coverage was not optimal, and disparities by race/ethnicity and other factors are apparent in coverage uptake. Tailored strategies are needed to educate the public and reduce disparities in COVID-19 vaccination coverage.
Identifiants
pubmed: 36480674
doi: 10.3201/eid2901.221151
pmc: PMC9796208
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-140Références
Influenza Other Respir Viruses. 2018 Nov;12(6):808-813
pubmed: 30028081
JAMA Netw Open. 2021 Sep 1;4(9):e2127582
pubmed: 34591103
Vaccine. 2021 Apr 8;39(15):2060-2067
pubmed: 33741191
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
MMWR Morb Mortal Wkly Rep. 2021 Oct 01;70(39):1365-1371
pubmed: 34591826
JAMA Netw Open. 2022 Jan 4;5(1):e2144470
pubmed: 35061038
Vaccine. 2018 Feb 1;36(6):890-898
pubmed: 29329685
N Engl J Med. 2022 Oct 6;387(14):1279-1291
pubmed: 36112399
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
Am J Prev Med. 2006 Oct;31(4):281-5
pubmed: 16979451
Am J Prev Med. 2019 Oct;57(4):458-469
pubmed: 31473066
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
Vaccine. 2013 Aug 20;31(37):3928-35
pubmed: 23806243
MMWR Surveill Summ. 2013 Oct 25;62(4):1-28
pubmed: 24157710
BMC Public Health. 2021 Jun 17;21(1):1166
pubmed: 34140009
Int J Environ Res Public Health. 2020 Jun 17;17(12):
pubmed: 32560363
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555
pubmed: 35421077
BMC Health Serv Res. 2018 Mar 27;18(1):220
pubmed: 29587721
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1723-1730
pubmed: 34914669
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
Nat Med. 2021 Jul;27(7):1298-1307
pubmed: 34007071
Econ Lett. 2021 Sep;206:109979
pubmed: 34230727
JAMA Netw Open. 2021 Oct 1;4(10):e2130343
pubmed: 34668949